JLK (322510, CEO Dongmin Kim), a stroke AI specialized company, announced that it will participate in the 'Stroke 2025' Japanese Stroke Society and 'KJJSC 2025' Korea-Japan Joint Stroke Conference, which will be held for three days from March 6, 2025 at the Osaka International Convention Center in Japan. Through this participation, JLK plans to fully advance into the Japanese medical AI market.
Stroke 2025 is a Japanese stroke-related academic event hosted by the Japan Stroke Society, where the latest stroke diagnosis and treatment technologies and research results are shared. JLK plans to focus on introducing its AI-based stroke solution at this event.
JLK will exhibit JLK-CTP, JLK-PWI, and NCCT AI solutions approved by the PMDA (Japan Pharmaceuticals and Medical Devices Agency). In particular, the NCCT (non-contrast CT) AI solution is receiving great attention from Japanese medical professionals as it can support rapid diagnosis of cerebral hemorrhage and cerebral infarction without using contrast agents. It is evaluated as an important technology in the Japanese market due to its high usability in emergency situations. In addition, FDA-approved solutions JBS-LVO, JLK-ICH, JLK-Ailink, JLK-SDH and domestic non-reimbursable application solution JBS-01K will also be exhibited.
JLK plans to accelerate its entry into the Japanese medical market by participating in Stroke 2025. The company is in the process of applying for PMDA approval and plans to rapidly expand its Japanese supply chain by finalizing agency contracts with major Japanese trading companies and medical device subsidiaries.
The industry is positive about JLK’s expansion into the Japanese market. In the Japanese medical market, demand for AI-based stroke solutions is increasing, and the Japanese government is implementing a policy that recognizes additional fees when AI solutions are used in hospitals above a certain size. Accordingly, JLK sees great market potential in Japan and is expected to quickly establish itself in the Japanese medical market.
In addition, the Korea-Japan Joint Stroke Conference will host a clinical seminar with the participation of major medical companies such as JLK, Bayer, and AstraZeneca. At the seminar, JLK will present on its stroke treatment experience and technological excellence using JLK’s AI solution together with Professor Kim Dong-eok (Dongguk University Ilsan Hospital), Professor Kim Beom-jun (Bundang Seoul National University Hospital), and Professor Manabu Inoue (National Cardiovascular Center, Japan).
JLK CEO Dongmin Kim said, “Our participation in Stroke 2025 will be an important turning point for JLK to fully enter the Japanese market,” and added, “Based on the PMDA-approved AI solution, we will rapidly expand our presence in the Japanese medical market and strengthen cooperation with local medical device distributors to achieve sales growth.”
CEO Kim continued, “Japan is a representative aging country, and the number of stroke patients is increasing every year, which is emerging as a social problem. Major hospitals in Japan are actively considering introducing AI-based solutions to improve the efficiency of acute stroke treatment, so expectations for JLK’s technology are high.”
- See more related articles
You must be logged in to post a comment.